BioOutsource facility passes US FDA inspection

By Gareth Macdonald

- Last updated on GMT

BioOutsource passes US FDA inspection (source: iStock/IvelinRadkov)
BioOutsource passes US FDA inspection (source: iStock/IvelinRadkov)

Related tags Sartorius stedim biotech Food and drug administration

A laboratory operated by recent Sartorius Stedim Biotech (SSB) acquisition BioOutsoruce has passed a GMP inspection by the US FDA.

The facility in Glasgow, Scotland – which provides analytical services that support the testing of biologics, vaccines and biosimilars – was visited by US Food and Drug Administration (FDA) inspectors in January.

BioOutsource CEO, Gerry MacKay told us “generally speaking, passing the FDA inspection in terms of the biologics market is a major accomplishment for us."

He added that: “Having our quality systems and analytical services certified is a big step towards welcoming new business from the US market​.” 

The facility passed an inspection by the UK Medicines and Healthcare Products Regulatory Agency (MHRA) in 2015 and – according to BioOutsource – has received similar positive reports from numerous biopharma clients.

BioOutsource​ was bought by SSB a year ago, which told us the Scotland-based services firm’s service portfolio had prompted the acquisition.

A few months later SSB increased its earnings guidance citing the contribution made by BioOutsource and its other recent acquisition Cellca​ as drivers for the revision.

Earlier this month SSB's parent company Sartorius reported that its bioprocess solutions division generated revenue of €809.2m ($887m) in 2015, an increase 20.9% on the previous year.

The firm said combined BioOutsource and Cellca had "contributed nearly two percentage points in constant currencies to the division's sales expansion​."

Related news

Show more

Related products

show more

eBook: mRNA prospects and scale-up solutions

eBook: mRNA prospects and scale-up solutions

Thermo Fisher Scientific - Biosciences | 22-Mar-2023 | Insight Guide

This mRNA eBook was created by Thermo Fisher Scientific, in collaboration with Genetic Engineering & Biotechnology News (GEN), to provide you with...

Create Better Biologic Treatments with Catalent

Create Better Biologic Treatments with Catalent

Catalent | 21-Feb-2023 | Product Brochure

Deliver safe and stable products to your patients with the help of Catalent Biologics' Limoges, France site, a European Center of Excellence for early-phase...

Trends in Biopharmaceutical Raw Material Selection

Trends in Biopharmaceutical Raw Material Selection

Actylis – The Partner of Choice | 31-Jan-2023 | Business Advice

Join us as our in-house experts, along with Cecile Bellamy from Pfizer, discuss current and future trends in biopharmaceutical raw material selection.

Related suppliers

Follow us

Products

View more

Webinars